Citi lowered the firm’s price target on Caribou Biosciences (CRBU) to $6 from $30 and keeps a Buy rating on the shares. The firm updated models in the Smid-cap biotech space following the Q3 reports. Citi adjusted its launch timelines for Caribou ‘s three cell therapies in development, saying its prior timelines were too aggressive.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter